NCT02064816View on ClinicalTrials.gov

A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis

PHASE4CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
DRUG

Rebif®

Rebif® will be administered at a dose of 44 microgram (mcg) subcutaneously three times a week in the morning using RebiSmart® self-injector device for 12 weeks.

DRUG

Rebif®

Rebif® will be administered at a dose of 44 mcg subcutaneously three times a week in the evening using RebiSmart® self-injector device for 12 weeks.

Trial Locations (1)

Unknown

Please contact the Merck KGaA Communication Center, Darmstadt

All Listed Sponsors
lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT02064816 - A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis | Biotech Hunter | Biotech Hunter